Medication info
Pregabalin Capsule 300 mg (Pregabalin)

Pregabalin Capsule 300 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Brown hard capsule with a white powder in the upper part and a white lower part
Packaging
30 capsules/bottle, 300 capsules/bottle
Approval status
Active

MFDS item code 201500516 · Approved 2015.01.30 · Insurance code 643507110

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dosage adjustment is required in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with or without secondary generalization
  • fibromyalgia
View approved original text

This medication is used in the treatment of peripheral and central neuropathic pain in adults. It is also very effective as an adjunct for partial seizures in epilepsy, both with or without secondary generalizations. Additionally, it helps to relieve pain in patients with fibromyalgia. It is used to improve various pain and spasms related to the nervous system.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dosage adjustment is required in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so any changes in mood or behavior during treatment should be reported to healthcare professionals immediately. Patients with hypersensitivity to this medication should not take it. Diabetic patients should be cautious as weight gain may require adjustments to their blood sugar control medications. If allergic reactions such as swelling around the face, mouth, or neck (angioedema) occur, the medication should be discontinued immediately. Elderly patients may experience increased dizziness or drowsiness, which can elevate the risk of falls, especially during the initial dose. If any unusual symptoms such as blurred vision or changes in eyesight occur, patients should consult their healthcare provider. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under medical guidance. Patients with a history of substance abuse should be monitored closely due to increased risk of misuse. Patients with reduced kidney function may need dose adjustments; kidney statuses should be assessed. Patients with heart failure should use caution when taking this medication, and those with heart conditions should consult their healthcare provider. Caution is advised when taking this medication along with opioid analgesics, as it can enhance central nervous system depressant effects and increase the risk of respiratory depression. Patients with weak respiratory function or the elderly may be at risk for severe respiratory depression, thus dose adjustment may be necessary. It is advisable to avoid this medication during early pregnancy due to the risk of congenital malformations in the fetus, and women of childbearing age should use effective contraceptive methods during treatment. Breastfeeding women are advised to discontinue breastfeeding as this medication can be transferred to breast milk and may affect the infant. Patients should be careful during activities that require alertness, such as driving or operating machinery, as dizziness or drowsiness may occur after taking this medication. If severe skin rashes or blisters develop, patients should stop taking the medication immediately and inform their healthcare provider. Overdose may result in drowsiness, confusion, depression, seizures, and may necessitate treatments such as hemodialysis if required. Keep this medication out of reach of children, and do not transfer it to another container for safety.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 175 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramping
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • poor appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • anxiety
  • mood swings
  • decreased emotions
  • elevated emotions
  • difficulty finding the right terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • movement coordination disorders
  • balance disorders
  • amnesia
  • attention disorders
  • memory impairment
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • tonic clonic seizures
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • taste loss
  • writing disorders
  • diplopia
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • agitation
  • restlessness
  • exacerbation of seizures
  • drowsiness
  • state of confusion
  • depression

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, in a cool place between 15°C and 30°C.

Appearance and packaging

Appearance

Brown hard capsule with a white powder in the upper part and a white lower part

Package unit

30 capsules/bottle, 300 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.